Lewy body dementia (LBD) is the second most common type of progressive dementia after Alzheimer's disease. It is caused by the abnormal accumulation of the protein alpha-synuclein within the brain, which forms spherical inclusions known as Lewy bodies. LBD shares symptoms with both Parkinson's disease and Alzheimer's disease. Common symptoms of LBD include visual hallucinations, parkinsonism, fluctuations in attention and alertness, and problems with thinking and memory. The diagnosis of LBD is based on clinical assessment and exclusion of other causes. Treatment focuses on managing symptoms and may include cholinesterase inhibitors, memanaine, and anti-psychotics.

The Global Lewy Body Dementia Market is estimated to be valued at USD 1.25 Bn in 2024 and is expected to reach USD 2.01 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

The growing geriatric population and rising prevalence of dementia globally is contributing to the growth of the Lewy Body Dementia Market.

Get more insights on : Lewy Body Dementia Market

Check out related topics for more valuable information - Pharmaceutical and Life Sciences Real World Evidence: Poised for Significant Growth